Clinical Trial Update: A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma [Phase 3]

View source ↗

Summary

Phase 3 randomized trial comparing busulfan + melphalan 140 mg/m2 vs melphalan 200 mg/m2 as conditioning for autologous stem cell transplantation in multiple my…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Busulfan + Melphalan 140 mg/m2
• Melphalan 200 mg/m2 (Melphalan)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myeloma | Phase 3 | Status: COMPLETED | Results posted: 2020-04-21